Autopsy report · NCT04044742

A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee

“To be replaced by a different protocol”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Sorrento Therapeutics, Inc.

Sponsor type

Industry

Conditions

Osteoarthritis, Knee; Knee Pain Chronic

Interventions

Resiniferatoxin; Placebo

Participants

0

Trials that died the same way

• Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
  “to be replaced with a different protocol” (100% match in meaning)
• Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
  “Replaced by another protocol” (96% match in meaning)
• RCT for Women With a Persisting Pregnancy of Unknown Location
  “A new protocol was written to replace this protocol.” (82% match in meaning)
• Bacteriophage Therapy in Patients With Prosthetic Joint Infections
  “Changes to protocol design” (81% match in meaning)
• Epidural Loading: High Volume, Low Concentration
  “The protocol will be rewritten.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.